PASIP
Research type
Research Study
Full title
Phenotyping of blood samples to detect Autoimmune Signatures following Immunotherapy with Pembrolizumab
IRAS ID
204755
Contact name
David Chao
Contact email
Sponsor organisation
Royal Free London NHS Foundation Trust
Duration of Study in the UK
2 years, 0 months, 1 days
Research summary
There is a new form of cancer treatment called immunotherapy which does not attack cancer directly but works on the immune system to make it more effective. This type of treatment may have side effects which are called autoimmune side effects and are caused by the immune system attacking the normal parts of the body. At the moment we cannot predict which patients may be at more risk of developing such autoimmune side effects and we also cannot predict which patients are more likely to benefit. This study will analyse blood samples from patients receiving immunotherapy to see if we can find markers to make such predictions.
REC name
London - Bromley Research Ethics Committee
REC reference
16/LO/1296
Date of REC Opinion
5 Jul 2016
REC opinion
Favourable Opinion